What is the administration frequency for Invega Sustenna?

Invega Sustenna, which contains the active ingredient paliperidone palmitate, is an atypical antipsychotic used primarily for the treatment of schizophrenia and schizoaffective disorder. The correct administration frequency for Invega Sustenna is monthly. This long-acting injectable formulation is designed to provide sustained therapeutic levels of the medication over a period of time, enhancing adherence to treatment for patients who may struggle with daily oral medication regimens.

The choice of monthly administration also aids in reducing the frequency of healthcare visits required by patients, allowing for more flexible management of their condition. Such a dosing schedule reflects the pharmacokinetic profile of the drug, ensuring that patients maintain adequate levels in their system to achieve therapeutic effects while minimizing potential side effects that could arise from fluctuating levels seen with more frequent dosing.

In contrast, options suggesting a weekly, every 3 months, or every 6 months administration frequency do not align with the recommended prescribing guidelines or pharmacodynamics of Invega Sustenna. These intervals would not provide the continuous therapeutic coverage needed for effective management of psychiatric symptoms, necessitating the choice of a monthly schedule.